Edward A Berger1. 1. Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. edward_berger@nih.gov
Abstract
PURPOSE OF REVIEW: HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described. RECENT FINDINGS: Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers. SUMMARY: These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.
PURPOSE OF REVIEW: HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described. RECENT FINDINGS: Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers. SUMMARY: These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.
Authors: R T Mitsuyasu; P A Anton; S G Deeks; D T Scadden; E Connick; M T Downs; A Bakker; M R Roberts; C H June; S Jalali; A A Lin; R Pennathur-Das; K M Hege Journal: Blood Date: 2000-08-01 Impact factor: 22.113
Authors: R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane Journal: Blood Date: 2000-07-15 Impact factor: 22.113
Authors: Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege Journal: Mol Ther Date: 2002-06 Impact factor: 11.454
Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg Journal: Blood Date: 2010-07-28 Impact factor: 22.113
Authors: P Ashorn; B Moss; J N Weinstein; V K Chaudhary; D J FitzGerald; I Pastan; E A Berger Journal: Proc Natl Acad Sci U S A Date: 1990-11 Impact factor: 12.779
Authors: Li Liu; Bhavik Patel; Mustafa H Ghanem; Virgilio Bundoc; Zhili Zheng; Richard A Morgan; Steven A Rosenberg; Barna Dey; Edward A Berger Journal: J Virol Date: 2015-04-15 Impact factor: 5.103
Authors: Paul W Denton; Julie M Long; Stephen W Wietgrefe; Craig Sykes; Rae Ann Spagnuolo; Olivia D Snyder; Katherine Perkey; Nancie M Archin; Shailesh K Choudhary; Kuo Yang; Michael G Hudgens; Ira Pastan; Ashley T Haase; Angela D Kashuba; Edward A Berger; David M Margolis; J Victor Garcia Journal: PLoS Pathog Date: 2014-01-09 Impact factor: 6.823
Authors: Perry Tsai; Guoxin Wu; Caroline E Baker; William O Thayer; Rae Ann Spagnuolo; Rosa Sanchez; Stephanie Barrett; Bonnie Howell; David Margolis; Daria J Hazuda; Nancie M Archin; J Victor Garcia Journal: Retrovirology Date: 2016-05-21 Impact factor: 4.602